<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837222</url>
  </required_header>
  <id_info>
    <org_study_id>C25022</org_study_id>
    <secondary_id>U1111-1258-8445</secondary_id>
    <nct_id>NCT04837222</nct_id>
  </id_info>
  <brief_title>A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma</brief_title>
  <official_title>Observational, Non-interventional, Multicenter Study Aimed at Collecting Prospective Data Related to Study Safety and Effectiveness in Real Clinical Practice in Patients With CD30+ Lymphoma (BRAVE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants with CD30-positive lympoma will be treated with brentuximab vedotin according to&#xD;
      their clinic's standard practice.&#xD;
&#xD;
      The main aim of this study is to collect information on any side effects from treatment with&#xD;
      brentuximab vedotin. Other aims are to collect information on how brentuximab vedotin is used&#xD;
      to treat these participants and the outcomes of these participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, non-interventional, prospective study in participants with&#xD;
      CD30-positive lymphoma who are receiving or will receive the standard treatment of&#xD;
      brentuximab vedotin. This study will assess the safety profile and effectiveness of&#xD;
      brentuximab vedotin in the real-world clinical practice.&#xD;
&#xD;
      The study will enroll approximately 1000 participants. The data will be collected and&#xD;
      recorded in the medical record for the purpose of medical care and also recorded in&#xD;
      electronic case report forms (e-CRFs). All the participants will be assigned to a single&#xD;
      observational cohort:&#xD;
&#xD;
      â€¢ All participants with CD30-positive lymphoma&#xD;
&#xD;
      This multi-center trial will be conducted in China. All participants will be followed up for&#xD;
      24 months unless withdrawal of Informed Consent, lost or death, whichever comes first. The&#xD;
      overall duration of the study will be approximately 4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting one or More Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting one or More Adverse Events (AEs)</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reporting one or More Adverse Drug Reactions (ADRs)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>ADRs refers to AE related to administered drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Dose Adjustments During the Study</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Based on Usage of Brentuximab Vedotin</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cycles of Brentuximub Vedotin Administered in Routine Clinical Practice</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Based on Disease Characteristics</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Number of participants will be reported based on the type of lymphoma, stage, lines of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Next Treatment (TTNT)</measure>
    <time_frame>From start of each line of therapy until next line of therapy (up to 4 years)</time_frame>
    <description>TTNT is defined as time between start of each line of a therapy to the next line of therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>ORR is defined as the percentage of participants with complete response (CR) and partial response (PR) after treatment in the total number of assessable cases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>From date of first documented CR until PD (up to 4 years)</time_frame>
    <description>DOR is calculated from the time of documentation of a CR to documentation of disease progression. CR is defined as disappearance of all residual disease and tumor lesions. Disease progression (PD) is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) Rate</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>PFS rate is calculated as the percentage of participants who reported PFS (at 1st year, 2nd year) as per investigator's assessment after brentuximab vedotin treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>OS rate is measured as the percentage of participants who reported death (at 1st year, 2nd year) after brentuximab vedotin treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Quality of Life (QoL) Assessed Using Functional Assessment of Cancer Therapy Lymphoma (FACT-Lym) Questionnaire Version 4</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The FACT-Lym questionnaire is a validated instrument for assessing the impact of lymphoma on health related quality of life and contains 42 questions covering health related quality of life, common lymphoma symptoms, and treatment side-effects. It contains four core subscales including: Physical Wellbeing, Social/Family Wellbeing, Emotional Wellbeing, and Functional Wellbeing. All questions are answered on a 5-point likert scale ranging from 0 to 4: 0=not at all,1=a little bit, 2=somewhat, 3=quite a bit, 4=very much. Higher scores are associated with a better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness Ratio</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Cost-effectiveness ratio will be assessed by the direct cost (including medication, injunction, test, nursing fee, etc.) under brentuximab vedotin treatment divided by the total percent of CR and PR.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Participants with CD30-positive Lymphoma</arm_group_label>
    <description>All participants diagnosed with CD30-positive lymphoma who are receiving or will recieve brentuximab vedotin will be observed prospectively over 24-month period, unless withdrawal of informed consent, lost or death, whichever comes first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No Intervention</intervention_name>
    <description>This is a non-interventional study.</description>
    <arm_group_label>Participants with CD30-positive Lymphoma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with CD30-positive lymphoma, who have been prescribed brentuximab vedotin in&#xD;
        clinical practice will be observed prospectively.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Undergoing treatment with brentuximab vedotin (of less than 3 months from initial&#xD;
             treatment with brentuximab vedotin) or to be received with brentuximab vedotin.&#xD;
&#xD;
          2. CD30-positive lymphoma by INV (any CD30 expression)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Who currently participates in or with plan to participate in any interventional clinical&#xD;
        trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Contact</last_name>
    <phone>+1-877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>18750918842</phone>
      <email>xubingzhangjian@126.com</email>
    </contact>
    <investigator>
      <last_name>Bing Xu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>13831177920</phone>
      <email>13831177920@163.com</email>
    </contact>
    <investigator>
      <last_name>Lihong Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Henan University of Science and Technology</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>13838837729</phone>
      <email>zzqq777@126.com</email>
    </contact>
    <investigator>
      <last_name>Ling Qin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HenanProvincial CancerHospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>13803846526</phone>
      <email>songyongping001@126.com</email>
    </contact>
    <investigator>
      <last_name>Yongping Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>15871725926</phone>
      <email>Lily1228@sina.com</email>
    </contact>
    <investigator>
      <last_name>LIling Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>18627091655</phone>
      <email>ghcui@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Guohui Cui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hodpital of Nantong University</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>13951300660</phone>
      <email>hongliu63@126.com</email>
    </contact>
    <investigator>
      <last_name>Hong Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>18560086990</phone>
      <email>wanglq@sdu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Luqun Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ShandongProvincial CancerHospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>13642138692</phone>
      <email>zengjunli@163.com</email>
    </contact>
    <investigator>
      <last_name>Zengjun Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>13512112076</phone>
      <email>zwl_trial@163.com</email>
    </contact>
    <investigator>
      <last_name>Weili Zhao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>18980601242</phone>
      <email>tingniu@sina.com</email>
    </contact>
    <investigator>
      <last_name>Ting Niu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Hospital of Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>15822412112</phone>
      <email>huangwenyang@ihcams.ac.cn</email>
    </contact>
    <investigator>
      <last_name>Wenyang Huang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>18622221228</phone>
      <email>zhlwgq@126.com</email>
    </contact>
    <investigator>
      <last_name>Huilai Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Affiliated People's Hospital of Ningbo University</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site Contact</last_name>
      <phone>13486090834</phone>
      <email>814871416@qq.com</email>
    </contact>
    <investigator>
      <last_name>Ying Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/60749a78688ad8001f42fb91</url>
    <description>To obtain more information on the study, click here/on this link</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 7, 2021</study_first_submitted>
  <study_first_submitted_qc>April 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

